Leases (Tables)

3 Months Ended

Sep. 30, 2025

The components of lease cost were as follows:


	Three months ended
	September 30, 2025		August 25, 2024
Finance lease cost:
Amortization of leased assets	$	40	$	36
Interest on lease liabilities	130		91
Operating lease cost	74		74


Total lease cost	$	244	$	201

Supplemental cash flow information related to leases are as follows:


	Three months ended
	September 30, 2025		August 25, 2024
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	102	$	101
Operating cash flows from finance leases	130		91
Financing cash flows from finance leases	39		40

The Company’s maturity analysis of operating and finance lease liabilities as of September 30, 2025 are as follows:


	Operating leases		Finance leases
Remainder of 2025	$	102	$	169
2026	$	410	$	691
2027	414		707
2028	144		725
2029	148		729
2030	153		724
Thereafter	347		5,975
Total lease payments	1,718		9,720
Less: interest	(136)		(3,806)
Present value of lease liabilities	$	1,582	$	5,914
Classification on consolidated balance sheet:
Accrued expenses and other current liabilities (see note 7)	$	368	$	174
Debt, net of current portion	—		5,740
Other liabilities	1,214		—
Present value of lease liabilities	$	1,582	$	5,914

The Company’s maturity analysis of operating and finance lease liabilities as of September 30, 2025 are as follows:


	Operating leases		Finance leases
Remainder of 2025	$	102	$	169
2026	$	410	$	691
2027	414		707
2028	144		725
2029	148		729
2030	153		724
Thereafter	347		5,975
Total lease payments	1,718		9,720
Less: interest	(136)		(3,806)
Present value of lease liabilities	$	1,582	$	5,914
Classification on consolidated balance sheet:
Accrued expenses and other current liabilities (see note 7)	$	368	$	174
Debt, net of current portion	—		5,740
Other liabilities	1,214		—
Present value of lease liabilities	$	1,582	$	5,914

LIFECORE BIOMEDICAL, INC. \DE\ 10-Q